Pharmaceutical Facilities Currently For Sale

Pharma facility valuations use standard real estate appraisal methodologies with specialized adjustments for the pharma layer. PharmaBioSource prices facilities based on validated capacity, regulatory standing, equipment fit, utility infrastructure, and proximity to talent and the supply chain — alongside the underlying real estate fundamentals. Comparable transactions come from our proprietary deal database, built since 2002, which supplements public real estate comps. The same facility sold to a CDMO and to a strategic acquirer often commands different valuations because the buyer’s intended use changes the asset’s value.

PharmaBioSource brokers GMP manufacturing facilities across biologics, small-molecule APIs, sterile injectable fill-finish, oral solid dose, vaccines, and cell and gene therapy modalities. Listings include fully validated sites and partially commissioned plants. Confidential listings are available to qualified buyers upon request.

Some sellers choose not to publicly list a facility for sale to protect operations, staff, and existing customer relationships. PharmaBioSource maintains a confidential roster of these facilities and matches them with qualified buyers under an NDA. To access confidential listings, qualified buyers can contact our brokerage team with an asset thesis or a modality requirement.

Yes. A sale-leaseback allows a pharma or biotech operator to unlock capital tied up in an owned facility while operations continue uninterrupted. PharmaBioSource structures sale-leasebacks using life sciences real estate comps, not generic industrial data.

PharmaBioSource represents buyers throughout the full transaction: facility evaluation, technical due diligence (utilities, cleanroom classification, equipment fit, and FDA inspection history), valuation, negotiation, and closing. The brokerage team works alongside buyer counsel and finance teams. Engagement begins at the listing inquiry and continues through the post-close transition.